Logo

BBOT

BridgeBio Oncology Therapeutics Inc.

BBOT

BridgeBio Oncology Therapeutics Inc. • NASDAQ
$12.31 ▲ 1.07% (+0.13)
Market Cap $984.66 M
52w High $14.04
52w Low $8.50
Dividend Yield 0%
P/E -8.49
Volume 38.00K
Outstanding Shares 79.99M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $49.181M ▲ $-44.757M ▼ 0% $-1.9 ▼ $-49M ▼
Q2-2025 $0 $30.093M ▲ $-28.435M ▼ 0% $0.039 ▲ $-29.912M ▼
Q1-2025 $0 $23.137M ▲ $-22.055M ▼ 0% $-0.02 ▼ $-23.083M ▼
Q4-2024 $0 $21.879M ▲ $-19.687M ▼ 0% $0.12 ▲ $-21.827M ▼
Q3-2024 $0 $19.664M $-17.323M 0% $0.1 $-19.612M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $468.285M ▲ $484.793M ▲ $38.093M ▼ $446.7M ▲
Q2-2025 $131.398M ▲ $151.253M ▼ $378.986M ▲ $-227.733M ▼
Q1-2025 $963.135K ▼ $195.678M ▲ $7.391M ▲ $188.287M ▼
Q4-2024 $1.698M ▼ $194.424M ▲ $5.708M ▲ $188.717M ▲
Q3-2024 $1.786M $192.333M $5.647M $186.686M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-44.757M ▼ $-70.626M ▼ $65.562M ▲ $383.988M ▲ $408.077M ▲ $-71.159M ▼
Q2-2025 $-28.435M ▼ $-23.293M ▼ $9.639M ▲ $18.956M ▲ $5.302M ▲ $-23.524M ▼
Q1-2025 $-487.392K ▼ $-734.642K ▼ $0 $0 $-734.642K ▼ $-734.642K ▼
Q4-2024 $1.953M ▲ $-87.859K ▲ $0 ▼ $0 ▼ $-87.859K ▼ $-87.859K ▲
Q3-2024 $-17.323M $-39.345M $37.914M $19.776M $-28.863K $-39.384M

Five-Year Company Overview

Income Statement

Income Statement BBOT looks like a very early-stage biotech with essentially no product revenue yet. Any recent profit figures are more a function of one‑off or accounting items than a sign of a mature, recurring business. The company is still firmly in the investment and development phase, where expenses are driven by research, clinical trials, and corporate setup rather than sales and marketing. Future results will likely swing around as trial spending ramps up and as any partnership or milestone payments appear, so near‑term earnings are not a reliable guide to long‑term potential.

Balance Sheet

Balance Sheet The balance sheet reflects a young, research‑focused company: modest assets, no reported debt, and equity funded primarily by investors rather than by accumulated profits. The lack of reported borrowing suggests a relatively clean capital structure, but it also means the company’s financial strength will depend heavily on how much cash it has actually raised and how carefully it manages that capital. As with many early biotechs, the main risk is not over‑indebtedness but the possibility that cash runs low before major clinical milestones are achieved, which could lead to further equity raises and ownership dilution.

Cash Flow

Cash Flow The reported cash flow data are minimal, which is common for a newly carved‑out biotech. In practice, investors should expect substantial cash outflows from operations as clinical trials progress, with little or no offsetting cash from product sales for several years. This means the business model is currently cash‑consuming, not cash‑generating. The company’s real financial flexibility will depend on prior and future fundraising, potential upfront or milestone payments from partners, and how efficiently it deploys cash across its pipeline.

Competitive Edge

Competitive Edge BBOT operates in a crowded but highly attractive oncology space, focusing on some of the most important and historically difficult cancer targets. Its edge comes from a differentiated scientific approach to the RAS and PI3K pathways, including drugs that can target both active and inactive forms of KRAS and a novel way of disrupting RAS–PI3K interactions. These features could help it stand out versus existing KRAS inhibitors and traditional PI3K drugs, especially if it can show better durability of response and fewer side effects. Still, competition is intense, with many large and small players pursuing similar cancer pathways, so clinical performance and speed of development will be critical to defending any advantage.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of BBOT’s story. The company is pursuing first‑in‑class and potentially best‑in‑class programs aimed at breaking resistance seen with earlier‑generation KRAS inhibitors and improving the safety profile of PI3K‑related therapies. Its three lead candidates all embody novel mechanisms, and the work is reinforced by collaborations with top research institutions and the legacy expertise of BridgeBio. All lead drugs are still in early human trials, so scientific promise has not yet been proven clinically. If early‑stage data validate the approach, BBOT could become a meaningful player in precision oncology; if not, its heavy research focus also amplifies scientific and development risk.

Summary

BBOT is a newly formed, clinical‑stage oncology company with an appealing scientific story but limited operating history and no commercial revenue yet. Financially, it is typical of early biotechs: investor‑funded, research‑heavy, and likely to consume cash for years before any potential product launches. Strategically, its focus on difficult but high‑value cancer targets, along with novel mechanisms and strong scientific partnerships, provides a credible path to differentiation, but everything still hinges on clinical trial outcomes. The next few years, especially as initial human data emerge, will be pivotal in determining whether the company’s innovative platform translates into durable medical and economic value or remains primarily a promising scientific concept.

NEWS

November 18, 2025 · 4:05 PM UTC

BBOT to Participate in Upcoming December Investor Healthcare Conferences

Read more

November 12, 2025 · 4:05 PM UTC

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Read more

November 3, 2025 · 4:05 PM UTC

BBOT to Participate in the Jefferies Global Healthcare Conference in London

Read more

October 30, 2025 · 5:45 PM UTC

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Read more

October 25, 2025 · 12:30 PM UTC

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

Read more